Press "Enter" to skip to content

France’s Sanofi to Buy US Biopharma Firm Kadmon in $1.9 Billion Deal

Amnon Free Press/Central Press Syndicate, USA. Read, Enjoy and Share the Latest US News Updates.

PARIS—French drugmaker Sanofi said on Wednesday it would buy U.S. biopharmaceutical company Kadmon Holdings for 1.9 billion dollars, one month after announcing the purchase of another US biotech, Translate Bio, for $3.2 billion. Sanofi said it has offered $9.50 per share in cash for Kadmon, representing a total equity value of approximately $1.9 billion on a fully diluted basis, and that both companies’ boards unanimously approved the transaction. Sanofi’s price tag represents a 79 percent premium on Kadmon’s $5.30 closing price on Tuesday. “The acquisition supports Sanofi’s strategy to continue to grow its general medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio,” the two companies said in a joint statement. Rezurock, a treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD), was approved in July by the U.S. Federal Drug Administration (FDA). “Kadmon’s pipeline includes drug candidates for immune …

To continue reading this news article, follow the link to the news website.

For any inquiries, contact Amnon Free Press (Amnon Jobi Jakony) by writing to editor [at] Discover a world of hyper-local news below.

Other News:   Baseball Report: Wild Card Races Heat Up With Just Four Weeks Of Regular Season Baseball Left

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *